bioRxiv · 10.1101/2024.09.15.612864
The lack of trade-off between conformational stability and binding affinity in a nanobody with therapeutic potential for a misfolding disease
Abstract
To improve protein pharmaceuticals, we need to balance protein stability and binding affinity with in vivo efficiency. We have recently developed a nanobody (NB-AGT-2) against the alanine:glyoxylate aminotransferase with high stability (Tm[~]85{degrees}C) that may be useful to treat a misfolding disease called primary hyperoxaluria type 1. In this work, we characterize the relationships between protein stability and binding affinity in NB-AGT-2 by generating single and double cavity-creating mutants in its hydrophobic core. These mutations decrease thermal stability by 10-20 {degrees}C, reflecting changes in thermodynamic stability of up to 8 kcal{middle dot}mol-1, hardly affecting their binding affinity for its target. Our results thus show that NB stability can be challenged without an effect on its binding.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Gomez-Mulas, A., Naganathan, A. N., Pey, A. L.. 2024-09-19. The lack of trade-off between conformational stability and binding affinity in a nanobody with therapeutic potential for a misfolding disease. https://doi.org/10.1101/2024.09.15.612864
Cite the original work for its findings. Save a collection to share your selection of sources.